;PMID: 9042254
;source_file_520.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:47..170] = [t:47..170]
;2)section:[e:174..284] = [t:174..284]
;3)section:[e:288..362] = [t:288..362]
;4)sentence:[e:366..501] = [t:366..501]
;5)sentence:[e:502..818] = [t:502..818]
;6)sentence:[e:819..997] = [t:819..997]
;7)sentence:[e:998..1107] = [t:998..1107]
;8)sentence:[e:1108..1284] = [t:1108..1284]
;9)sentence:[e:1285..1372] = [t:1285..1372]
;10)sentence:[e:1373..1475] = [t:1373..1475]
;11)sentence:[e:1477..1587] = [t:1477..1587]
;12)sentence:[e:1588..1718] = [t:1588..1718]
;13)sentence:[e:1719..1875] = [t:1719..1875]
;14)section:[e:1879..1923] = [t:1879..1923]

;section 0 Span:0..42
;Anticancer Res  1996 Nov-Dec;16(6B):3761-6
(SEC
  (FRAG (VBG:[0..10] Anticancer) (NNP:[11..14] Res) (CD:[16..20] 1996)
        (HYPH:[21..25] Nov-) (CD:[25..32] Dec;16-LRB-) (CD:[32..35] 6B-RRB-)
        (CD:[35..40] :3761) (HYPH:[40..41] -) (CD:[41..42] 6)))

;sentence 1 Span:47..170
;Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras
;in  malignant neuroendocrine pancreatic tumor.
;[59..73]:variation-type:"point mutation"
;[99..102]:gene-rna:"p53"
;[116..123]:gene-rna:"c-N-ras"
;[128..169]:malignancy:"malignant neuroendocrine pancreatic tumor"
(SENT
  (NP-HLN
    (NP (JJ:[47..58] Concomitant)
       (NN:[59..64] point) (NN:[65..73] mutation))
    (PP (IN:[74..76] of)
      (NP
        (NP
          (NP (NN:[77..82] tumor) (NN:[83..93] suppressor) (NN:[94..98] gene))
          (NP (NN:[99..102] p53)))
        (CC:[103..106] and)
        (NP
          (NP (NN:[107..115] oncogene))
          (NP (NN:[116..123] c-N-ras)))))
    (PP-LOC (IN:[124..126] in)
      (NP (JJ:[128..137] malignant) (JJ:[138..152] neuroendocrine)
          (JJ:[153..163] pancreatic) (NN:[164..169] tumor)))
    (.:[169..170] .)))

;section 2 Span:174..284
;Hrascan R, Pavelic K, Pavicic D, Krizanac S, Stajcer-Sittic V, Pecur L,
;Spaventi  S, Klimpfinger M, Pavelic J.
(SEC
  (FRAG (NNP:[174..181] Hrascan) (NNP:[182..184] R,) (NNP:[185..192] Pavelic)
        (NNP:[193..194] K) (,:[194..195] ,) (NNP:[196..203] Pavicic)
        (NNP:[204..205] D) (,:[205..206] ,) (NNP:[207..215] Krizanac)
        (NNP:[216..218] S,) (NNP:[219..226] Stajcer) (HYPH:[226..227] -)
        (NNP:[227..233] Sittic) (NNP:[234..235] V) (,:[235..236] ,)
        (NNP:[237..242] Pecur) (NNP:[243..245] L,) (NNP:[246..254] Spaventi)
        (NNP:[256..258] S,) (NNP:[259..270] Klimpfinger) (NNP:[271..273] M,)
        (NNP:[274..281] Pavelic) (NNP:[282..284] J.)))

;section 3 Span:288..362
;Division of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
(SEC
  (FRAG (NNP:[288..296] Division) (IN:[297..299] of) (NNP:[300..309] Molecular)
        (NNP:[310..318] Medicine) (,:[318..319] ,) (NNP:[320..325] Ruder)
        (NNP:[326..334] Boskovic) (NNP:[335..344] Institute) (,:[344..345] ,)
        (NNP:[346..352] Zagreb) (,:[352..353] ,) (NNP:[354..361] Croatia)
        (.:[361..362] .)))

;sentence 4 Span:366..501
;Activation by point mutation of ras family genes as well as point mutations
;of  the p53 tumor suppressor gene are found in many tumors.
;[380..394]:variation-type:"point mutation"
;[398..401]:gene-rna:"ras"
;[426..441]:variation-type:"point mutations"
;[450..453]:gene-rna:"p53"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (NN:[366..376] Activation))
        (PP (IN:[377..379] by)
          (NP (NN:[380..385] point) (NN:[386..394] mutation)))
        (PP (IN:[395..397] of)
          (NP
            (NML (NN:[398..401] ras) (NN:[402..408] family))
            (NNS:[409..414] genes))))
      (CONJP (RB:[415..417] as) (RB:[418..422] well) (IN:[423..425] as))
      (NP
        (NP (NN:[426..431] point) (NNS:[432..441] mutations))
        (PP (IN:[442..444] of)
          (NP (DT:[446..449] the) (NN:[450..453] p53)
            (NML (NN:[454..459] tumor) (NN:[460..470] suppressor))
            (NN:[471..475] gene)))))
    (VP (VBP:[476..479] are)
      (VP (VBN:[480..485] found)
        (NP-1 (-NONE-:[485..485] *))
        (PP-LOC (IN:[486..488] in)
          (NP (JJ:[489..493] many) (NNS:[494..500] tumors)))))
    (.:[500..501] .)))

;sentence 5 Span:502..818
;Here we describe a rare  case of malignant neuroendocrine pancreatic tumor
;with multiple metastases in  different organs showing strong positivity for
;synaptophysin, glucagon-like  peptide 1, pan-cytokeratin, moderate positivity
;for chromogranin, Phe-5 and  calcitonin and weak positivity for
;vasointestinal peptide.
;[535..576]:malignancy:"malignant neuroendocrine pancreatic tumor"
;[591..601]:malignancy:"metastases"
;[653..666]:gene-protein:"synaptophysin"
;[668..692]:gene-protein:"glucagon-like  peptide 1"
;[694..709]:gene-protein:"pan-cytokeratin"
;[735..747]:gene-protein:"chromogranin"
;[749..754]:gene-protein:"Phe-5"
;[760..770]:gene-protein:"calcitonin"
;[795..817]:gene-protein:"vasointestinal peptide"
(SENT
  (S
    (ADVP (RB:[502..506] Here))
    (NP-SBJ (PRP:[507..509] we))
    (VP (VBP:[510..518] describe)
      (NP
        (NP (DT:[519..520] a) (JJ:[521..525] rare) (NN:[527..531] case))
        (PP (IN:[532..534] of)
          (NP
            (NP
              (NP (JJ:[535..544] malignant) (JJ:[545..559] neuroendocrine)
                  (JJ:[560..570] pancreatic) (NN:[571..576] tumor))
              (PP (IN:[577..581] with)
                (NP
                  (NP (JJ:[582..590] multiple) (NNS:[591..601] metastases))
                  (PP-LOC (IN:[602..604] in)
                    (NP (JJ:[606..615] different) (NNS:[616..622] organs))))))
            (VP (VBG:[623..630] showing)
              (NP
                (NP
                  (NP (JJ:[631..637] strong) (NN:[638..648] positivity))
                  (PP (IN:[649..652] for)
                    (NP (NN:[653..666] synaptophysin))))
                (,:[666..667] ,)
                (NP
                  (ADJP (NN:[668..676] glucagon) (HYPH:[676..677] -)
                        (JJ:[677..681] like))
                  (NN:[683..690] peptide) (CD:[691..692] 1))
                (,:[692..693] ,)
                (NP (NN:[694..709] pan-cytokeratin))
                (,:[709..710] ,)
                (NP
                  (NP (JJ:[711..719] moderate) (NN:[720..730] positivity))
                  (PP (IN:[731..734] for)
                    (NP (NN:[735..747] chromogranin) (,:[747..748] ,)
                        (NN:[749..754] Phe-5) (CC:[755..758] and)
                        (NN:[760..770] calcitonin))))
                (CC:[771..774] and)
                (NP
                  (NP (JJ:[775..779] weak) (NN:[780..790] positivity))
                  (PP (IN:[791..794] for)
                    (NP (JJ:[795..809] vasointestinal) (NN:[810..817] peptide))))))))))
    (.:[817..818] .)))

;sentence 6 Span:819..997
;We found a point  mutation at codon 61 of the c-N-ras oncogene, and point
;mutations in the p53  tumor suppressor gene in the primary tumor as well as
;in its metastases in  liver.
;[830..845]:variation-type:"point  mutation"
;[849..857]:variation-location:"codon 61"
;[865..872]:gene-rna:"c-N-ras"
;[887..902]:variation-type:"point mutations"
;[910..913]:gene-rna:"p53"
;[944..957]:malignancy:"primary tumor"
;[976..996]:malignancy:"metastases in  liver"
(SENT
  (S
    (NP-SBJ (PRP:[819..821] We))
    (VP (VBD:[822..827] found)
      (NP
        (NP
          (NP (DT:[828..829] a)
             (NN:[830..835] point) (NN:[837..845] mutation))
          (PP-LOC (IN:[846..848] at)
            (NP
              (NP (NN:[849..854] codon) (CD:[855..857] 61))
              (PP (IN:[858..860] of)
                (NP (DT:[861..864] the) (NN:[865..872] c-N-ras)
                    (NN:[873..881] oncogene))))))
        (,:[881..882] ,) (CC:[883..886] and)
        (NP
          (NP (NN:[887..892] point) (NNS:[893..902] mutations))
          (PP-LOC (IN:[903..905] in)
            (NP (DT:[906..909] the) (NN:[910..913] p53)
              (NML (NN:[915..920] tumor) (NN:[921..931] suppressor))
              (NN:[932..936] gene)))
          (PP-LOC
            (PP (IN:[937..939] in)
              (NP (DT:[940..943] the)
                 (JJ:[944..951] primary) (NN:[952..957] tumor)))
            (CONJP (RB:[958..960] as) (RB:[961..965] well) (IN:[966..968] as))
            (PP (IN:[969..971] in)
              (NP
                (NP (PRP$:[972..975] its) (NNS:[976..986] metastases))
                (PP (IN:[987..989] in)
                  (NP (NN:[991..996] liver)))))))))
    (.:[996..997] .)))

;sentence 7 Span:998..1107
;The mutation in the c-N-ras gene was a cytosine to adenine transversion, 
;resulting in the amino-acid lysine.
;[1002..1010]:variation-event:"mutation"
;[1018..1025]:gene-rna:"c-N-ras"
;[1037..1045]:variation-state-original:"cytosine"
;[1049..1056]:variation-state-altered:"adenine"
;[1057..1069]:variation-type:"transversion"
;[1100..1106]:variation-state-altered:"lysine"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[998..1001] The) (NN:[1002..1010] mutation))
      (PP-LOC (IN:[1011..1013] in)
        (NP (DT:[1014..1017] the) (NN:[1018..1025] c-N-ras)
            (NN:[1026..1030] gene))))
    (VP (VBD:[1031..1034] was)
      (NP-PRD
        (NP (DT:[1035..1036] a)
          (NML
            (NML (NN:[1037..1045] cytosine))
            (PP (TO:[1046..1048] to)
              (NP (NN:[1049..1056] adenine))))
          (NN:[1057..1069] transversion))
        (,:[1069..1070] ,)
        (VP (VBG:[1072..1081] resulting)
          (PP-CLR (IN:[1082..1084] in)
            (NP
              (NP (DT:[1085..1088] the) (JJ:[1089..1094] amino)
                  (HYPH:[1094..1095] -) (NN:[1095..1099] acid))
              (NP (NN:[1100..1106] lysine)))))))
    (.:[1106..1107] .)))

;sentence 8 Span:1108..1284
;Allele specific hybridization showed that  the mutation involved one of two
;c-N-ras alleles as the oligonucleotide for the  normal codon also hybridized
;to amplified tumor DNA.
;[1155..1163]:variation-event:"mutation"
;[1184..1191]:gene-rna:"c-N-ras"
(SENT
  (S
    (NP-SBJ
      (ADJP (NN:[1108..1114] Allele) (JJ:[1115..1123] specific))
      (NN:[1124..1137] hybridization))
    (VP (VBD:[1138..1144] showed)
      (SBAR (IN:[1145..1149] that)
        (S
          (NP-SBJ (DT:[1151..1154] the) (NN:[1155..1163] mutation))
          (VP (VBD:[1164..1172] involved)
            (NP
              (NP (CD:[1173..1176] one))
              (PP (IN:[1177..1179] of)
                (NP (CD:[1180..1183] two) (NN:[1184..1191] c-N-ras)
                    (NNS:[1192..1199] alleles))))
            (SBAR-ADV (IN:[1200..1202] as)
              (S
                (NP-SBJ
                  (NP (DT:[1203..1206] the) (NN:[1207..1222] oligonucleotide))
                  (PP (IN:[1223..1226] for)
                    (NP (DT:[1227..1230] the) (JJ:[1232..1238] normal)
                        (NN:[1239..1244] codon))))
                (ADVP (RB:[1245..1249] also))
                (VP (VBD:[1250..1260] hybridized)
                  (PP-CLR (TO:[1261..1263] to)
                    (NP (VBN:[1264..1273] amplified) (NN:[1274..1279] tumor)
                        (NN:[1280..1283] DNA))))))))))
    (.:[1283..1284] .)))

;sentence 9 Span:1285..1372
;Concomitant mutation of the  p53 tumor suppressor gene at codons 248 and 249
;was found.
;[1297..1305]:variation-event:"mutation"
;[1314..1317]:gene-rna:"p53"
;[1343..1353]:variation-location:"codons 248"
;[1343..1349]...[1358..1361]:variation-location:"codons"..."249"
(SENT
  (S
    (NP-SBJ-2
      (NP (JJ:[1285..1296] Concomitant) (NN:[1297..1305] mutation))
      (PP (IN:[1306..1308] of)
        (NP (DT:[1309..1312] the) (NN:[1314..1317] p53)
          (NML (NN:[1318..1323] tumor) (NN:[1324..1334] suppressor))
          (NN:[1335..1339] gene)))
      (PP-LOC (IN:[1340..1342] at)
        (NP
          (NP
            (NML-1 (NNS:[1343..1349] codons))
            (CD:[1350..1353] 248))
          (CC:[1354..1357] and)
          (NP
            (NML-1 (-NONE-:[1357..1357] *P*))
            (CD:[1358..1361] 249)))))
    (VP (VBD:[1362..1365] was)
      (VP (VBN:[1366..1371] found)
        (NP-2 (-NONE-:[1371..1371] *))))
    (.:[1371..1372] .)))

;sentence 10 Span:1373..1475
;The mutation in codon  248 was a cytosine to guanine transversion resulting
;in the amino-acid glycine.
;[1377..1385]:variation-event:"mutation"
;[1389..1399]:variation-location:"codon  248"
;[1406..1414]:variation-state-original:"cytosine"
;[1418..1425]:variation-state-altered:"guanine"
;[1426..1438]:variation-type:"transversion"
;[1467..1474]:variation-state-altered:"glycine"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1373..1376] The) (NN:[1377..1385] mutation))
      (PP-LOC (IN:[1386..1388] in)
        (NP (NN:[1389..1394] codon) (CD:[1396..1399] 248))))
    (VP (VBD:[1400..1403] was)
      (NP-PRD
        (NP (DT:[1404..1405] a)
          (NML
            (NML (NN:[1406..1414] cytosine))
            (PP (TO:[1415..1417] to)
              (NP (NN:[1418..1425] guanine))))
          (NN:[1426..1438] transversion))
        (VP (VBG:[1439..1448] resulting)
          (PP-CLR (IN:[1449..1451] in)
            (NP
              (NP (DT:[1452..1455] the) (JJ:[1456..1461] amino)
                  (HYPH:[1461..1462] -) (NN:[1462..1466] acid))
              (NP (NN:[1467..1474] glycine)))))))
    (.:[1474..1475] .)))

;sentence 11 Span:1477..1587
;The mutation in codon 249 was a third base, G- > T, transversion leading to a
; change from arginine to serine.
;[1481..1489]:variation-event:"mutation"
;[1493..1502]...[1509..1519]:variation-location:"codon 249"..."third base"
;[1521..1522]:variation-state-original:"G"
;[1526..1527]:variation-state-altered:"T"
;[1529..1541]:variation-type:"transversion"
;[1568..1576]:variation-state-original:"arginine"
;[1580..1586]:variation-state-altered:"serine"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1477..1480] The) (NN:[1481..1489] mutation))
      (PP-LOC (IN:[1490..1492] in)
        (NP (NN:[1493..1498] codon) (CD:[1499..1502] 249))))
    (VP (VBD:[1503..1506] was)
      (NP-PRD
        (NP (DT:[1507..1508] a)
          (NML (JJ:[1509..1514] third) (NN:[1515..1519] base))
          (,:[1519..1520] ,)
          (NML
            (NML (NN:[1521..1522] G))
            (PP (SYM:[1522..1523] -) (SYM:[1524..1525] >)
              (NP (NN:[1526..1527] T))))
          (,:[1527..1528] ,) (NN:[1529..1541] transversion))
        (VP (VBG:[1542..1549] leading)
          (PP (TO:[1550..1552] to)
            (NP
              (NP (DT:[1553..1554] a) (NN:[1556..1562] change))
              (PP (IN:[1563..1567] from)
                (NP (NN:[1568..1576] arginine)))
              (PP (TO:[1577..1579] to)
                (NP (NN:[1580..1586] serine))))))))
    (.:[1586..1587] .)))

;sentence 12 Span:1588..1718
;This is the first time that concomitant point  mutations in c-N-ras and p53
;have been found in a neuroendocrine pancreatic  tumor.
;[1628..1644]:variation-type:"point  mutations"
;[1648..1655]:gene-rna:"c-N-ras"
;[1660..1663]:gene-rna:"p53"
;[1685..1717]:malignancy:"neuroendocrine pancreatic  tumor"
(SENT
  (S
    (NP-SBJ (DT:[1588..1592] This))
    (VP (VBZ:[1593..1595] is)
      (NP-PRD (DT:[1596..1599] the) (JJ:[1600..1605] first)
              (NN:[1606..1610] time)
        (SBAR (IN:[1611..1615] that)
          (S
            (NP-SBJ-1
              (NP (JJ:[1616..1627] concomitant)
                 (NN:[1628..1633] point) (NNS:[1635..1644] mutations))
              (PP-LOC (IN:[1645..1647] in)
                (NP (NN:[1648..1655] c-N-ras) (CC:[1656..1659] and)
                    (NN:[1660..1663] p53))))
            (VP (VBP:[1664..1668] have)
              (VP (VBN:[1669..1673] been)
                (VP (VBN:[1674..1679] found)
                  (NP-1 (-NONE-:[1679..1679] *))
                  (PP-LOC (IN:[1680..1682] in)
                    (NP (DT:[1683..1684] a)
                       (JJ:[1685..1699] neuroendocrine)
                       (JJ:[1700..1710] pancreatic) (NN:[1712..1717] tumor))))))))))
    (.:[1717..1718] .)))

;sentence 13 Span:1719..1875
;Based upon these and our previous results, we concluded that these  genetic
;changes may play a role in the development of this particular pancreatic 
;tumor.
;[1857..1874]:malignancy:"pancreatic  tumor"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[1719..1719] *))
      (VP (VBN:[1719..1724] Based)
        (PP-CLR (IN:[1725..1729] upon)
          (NP
            (NP (DT:[1730..1735] these))
            (CC:[1736..1739] and)
            (NP (PRP$:[1740..1743] our) (JJ:[1744..1752] previous)
                (NNS:[1753..1760] results))))))
    (,:[1760..1761] ,)
    (NP-SBJ (PRP:[1762..1764] we))
    (VP (VBD:[1765..1774] concluded)
      (SBAR (IN:[1775..1779] that)
        (S
          (NP-SBJ (DT:[1780..1785] these) (JJ:[1787..1794] genetic)
                  (NNS:[1795..1802] changes))
          (VP (MD:[1803..1806] may)
            (VP (VB:[1807..1811] play)
              (NP (DT:[1812..1813] a) (NN:[1814..1818] role))
              (PP (IN:[1819..1821] in)
                (NP
                  (NP (DT:[1822..1825] the) (NN:[1826..1837] development))
                  (PP (IN:[1838..1840] of)
                    (NP (DT:[1841..1845] this) (JJ:[1846..1856] particular)
                       (JJ:[1857..1867] pancreatic) (NN:[1869..1874] tumor))))))))))
    (.:[1874..1875] .)))

;section 14 Span:1879..1923
;PMID: 9042254 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1879..1883] PMID) (::[1883..1884] :) (CD:[1885..1892] 9042254)
        (IN:[1893..1894] -LSB-) (NNP:[1894..1900] PubMed) (HYPH:[1901..1902] -)
        (JJ:[1903..1910] indexed) (IN:[1911..1914] for)
        (NNP:[1915..1923] MEDLINE-RSB-)))
